Figure 2.

Design of rVSV∆G-MARV-GP preclinical dose-range efficacy study conducted in cynomolgus macaques. (A) Timing of activities during the course of the study are shown at the top and a table summarizing study design is shown below. The control rVSV∆G-based Lassa virus vaccine material (rVSV∆G-LASV-GPC; [45,53]) was produced from a new recombinant strain (IAVI unpublished). (B) Animal survival after MARV Angola challenge. (C) MARV viremia quantified by plaque assay at the indicated timepoints post viral challenge. Limit of detection (LOD) = 25 PFU/mL.